Completed enrollment with 530 subjects in the pivotal phase 3 PHOENIX trial in geographic atrophy (GA)Completed $15 million ...
Announced pivotal topline data from Phase I/II study of AMT-130 in Huntington’s disease met its primary and key secondary endpoints, demonstrating statistically significant slowing of disease progress ...
Third Quarter 2025 Financial Highlights - Cash Position : Cash and cash equivalents were $81.3 million as of September 30, 2025, compared to $90.4 million as of June 30, 2025. - Revenue : ...
Seoul: A North Korea-linked hacking group has launched a new form of cyberattack that remotely controls Android smartphones ...
Astronomers confirm that 3I/Atlas is still intact, despite viral posts claiming it was destroyed near the Sun.
Year, and Adjusted EBITDA of $11.7 Million, up 34% Year-Over YearNine MonthRevenue of $135.8 Million, up 11% Year-over-Year; Adjusted EBITDA of $34.2 Million, up 35% Year-over-Year Positive Outlook ...
New preclinical data for PM577 in Wilson’s Disease (WD) to be presented at AASLD; on-track to file IND and/or CTA in H1’26, with initial ...
Received CTA authorization for Phase 1 trial of lead program AX-0810, targeting NTCP for cholestatic diseasesInitiating Phase 1 study of AX-0810 in healthy volunteers, with initial safety, tolerabilit ...
PRIMETIMER on MSN
After weeks out of sight, comet 3I/Atlas reemerges for viewing — here’s what astronomers are noticing now
Scientists have confirmed that comet 3I/Atlas is visible again following its close approach to the Sun, sparking fresh ...
HCA Healthcare, Inc. ( HCA) UBS Global Healthcare Conference 2025 November 12, 2025 9:30 AM EST ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback